

# CORRECTIONS & AMENDMENTS

## CORRECTION

<https://doi.org/10.1038/s41586-019-0974-0>

### Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

David M. Hyman, Sarina A. Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I. Shapiro, Dejan Juric, David I. Quinn, Victor Moreno, Bernard Doger, Ingrid A. Mayer, Valentina Boni, Emiliano Calvo, Sherene Loi, Albert C. Lockhart, Joseph P. Erinjeri, Maurizio Scaltriti, Gary A. Ulaner, Juber Patel, Jiabin Tang, Hannah Beer, S. Duygu Selcuklu, Aphrothiti J. Hanrahan, Nancy Bouvier, Myra Melcer, Rajmohan Murali, Alison M. Schram, Lillian M. Smyth, Komal Jhaveri, Bob T. Li, Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler Jr, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard P. Bryce, Carlos L. Arteaga, Funda Meric-Bernstam, José Baselga & David B. Solit

Correction to: *Nature* <https://doi.org/10.1038/nature25475>, published online 31 January 2018.

In the interests of transparency, the authors wish to amend the Competing Interests statement of this Article to read as follows (author initials are in boldface): **R.E.C.**, **F.X.**, **L.D.E.**, **G.M.**, **C.F.**, **A.S.L.** and **R.P.B.** are employees of Puma Biotechnology. **D.M.H.** reports, regardless of relevance, receipt of personal fees from Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim and AstraZeneca, and research funding from Puma Biotechnology, AstraZeneca and Loxo Oncology. **B.T.L.** reports research funding from Daiichi-Sankyo. **A.D.** reports personal fees from Roche. **D.B.S.** reports receipt of personal fees from Loxo Oncology and Pfizer. **J.P.E.** is a consultant for BTG International, AstraZeneca and Canon USA. **I.A.M.** reports receipt of personal fees from Novartis, Genentech Lilly, AstraZeneca, GlaxoSmithKline, Immunomedics, MacroGenics and Seattle Genetics, and research funding to her institution (Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA) from Novartis, Genentech and Pfizer. **F.M.-B.** reports grants from Novartis, AstraZeneca, Calithera, Bayer, Jounce Therapeutics, CytomX, eFFECTOR, Zymeworks, Puma Biotechnology, Curis, Takeda-Millennium, Daiichi-Sankyo, AbbVie, Guardant Health and Takeda, as well as grants and travel-related fees from Taiho, Genentech, Debiopharm Group and Pfizer. **F.M.-B.** also served as a consultant to Pieris Pharmaceuticals, Dialectica, Sumitomo Dainippon, Samsung Bioepis, Aduro, OrigiMed, Xencor and Jackson Laboratory, and as an advisor to Inflection Biosciences, GRAIL, Darwin Health, Clearlight Diagnostics, Spectrum and Mersana. **L.M.S.** reports receipt of personal fees from Roche/Genentech, AstraZeneca and Pfizer, and research funding to her institution from Puma Biotechnology, AstraZeneca and Roche/Genentech, and funding for travel, accommodation and expenses from Pfizer. **M.S.** reports research funding from Puma Biotechnology, Daiichi-Sankyo, Immunomedics, Targimmune and Menarini Ricerche, is a cofounder of Medendi Medical Travel and serves on the advisory boards of The Bioscience Institute and Menarini Ricerche. **G.A.U.** reports receipt of personal fees from Sanofi and grants from Sanofi, Novartis and Genentech. **J.B.** reports non-financial support and reasonable reimbursement for travel from Roche/Genentech; receipt of fees from and stock ownership in the following companies: Aura Biosciences (including serving on the board of directors 2013–2017), Infinity

Pharmaceuticals (including serving on the board of directors 2013–2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board 2014 to the present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board 2014–2017), GRAIL, (including serving as member or chair of the scientific advisory board 2016–2018), Varian Medical Systems (including serving on the board of directors 2017–2018), Bristol-Myers Squibb (including serving on the board of directors March–September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board 2013–2014). **J.B.** also reports stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board 2014 to the present) and Foghorn Therapeutics (including serving on the board 2017 to the present); serving as cofounder of, receipt of fees from and stock ownership in Tango (formerly Synthetic Lethal) (2016 to the present) and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board 2013 to the present); receipt of consulting and travel fees from Novartis and Eli Lilly; and serving as cofounder of Venthera. **J.B.** also reports serving as investigator on a patent licensed to Memorial Sloan Kettering for use of phosphoinositide-3-kinase (**PI3K**) inhibitors for treatment of vascular malformations and serving as investigator for patents pending assignment to Memorial Sloan Kettering for combination therapy using PDK1 and PI3K inhibitors and inhibition of KMT2D for the treatment of breast cancer. **S.A.P.-P.** receives research funding from AbbVie, Aminex Therapeutics, BioMarin Pharmaceutical, Bristol-Myers Squibb, Curis, Five Prime Therapeutics, Genmab, GlaxoSmithKline, Helix BioPharma, Incyte, Medivation, Merck Sharp & Dohme, Novartis, Pieris Pharmaceuticals, Pfizer, Puma Biotechnology, Taiho Oncology, Tesaro and TransThera Bio. **K.J.** reports receipt of personal fees from Novartis, AstraZeneca, Spectrum Pharmaceuticals, ADC Therapeutics, Pfizer, Bristol-Myers Squibb, Taiho Oncology and Jounce Therapeutics, and institutional research funding from Novartis, Clovis Oncology, Genentech, AstraZeneca, ADC Therapeutics, Novita Pharmaceuticals, Debio Pharmaceuticals, Pfizer and Eli Lilly. **J.J.H.** reports receipt of personal fees from Bristol-Myers Squibb and Eli Lilly, and research funding from Bristol-Myers Squibb. **J.R.** reports non-financial support and reasonable reimbursement for travel from the European Journal of Cancer, Vall d'Hebron Institut of Oncology, the Chinese University of Hong Kong, SOLTI, Elsevier and GlaxoSmithKline, and receipt of consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma (including serving on the scientific advisory board 2015 to the present). **J.R.** also reports receipt of research funding from Bayer and Novartis, and serving as an investigator in clinical trials with Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAtla, Pfizer, Genmab, CytomX, Kelun Biotech, Takeda-Millennium, GlaxoSmithKline and IPSEN. **C.S.** reports research funding to her institution (Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain) from AstraZeneca, Roche/Genentech and Puma, and served as a consultant, participated in advisory boards or received travel grants from AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Roche, Genomic Health, Novartis, Pfizer, Pierre Fabre, Puma and Synthron. **C.L.A.** served as a consultant for Genentech and Puma Biotechnology. **G.I.S.** reports support from PUMA to the Dana-Farber Cancer Institute for the conduct of the study. **G.I.S.** also reports (for work not directly related to this Article) receipt of grants and personal fees from Lilly, grants and personal fees from Merck/EMD Serono, grants and personal fees from Sierra Oncology, grants from Merck, grants and personal fees from Pfizer, grants from Array, personal fees

# CORRECTIONS & AMENDMENTS

---

from G1 Therapeutics, personal fees from Bicycle Therapeutics, personal fees from Fusion Pharmaceuticals, personal fees from Bayer, and personal fees from Cybrexa Therapeutics, Astex, Almac, Ipsen and Roche. In addition, **G.I.S.** has a US patent no. 9872874, 'Dosage regimen for sapacitabine and seliciclib', issued to Geoffrey I. Shapiro and Cyclacel Pharmaceuticals, and a provisional US patent application no. 62/538,319, 'Compositions and methods for predicting response and resistance to CDK4/6 inhibition', pending to Geoffrey I. Shapiro and Liam Cornell. **D.J.** reports personal fees from Novartis, Genentech, EMD Serono, Eisai and Ipsen. **E.C.** is employed by START and HM Hospitals Group, where he holds a leadership position; he has equity ownership at START, Oncoart Associated and International Cancer

Consultants; he receives honoraria from HM Hospitals Group, and he is the founder and president of the INTHEOS (Investigational Therapeutics in Oncological Sciences) Foundation. In the past two years (2017 to 2018), **E.C.** has been a paid consultant or advisor to Novartis, Nanobiotix, Janssen-Cilag, PsiOxus Therapeutics, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, Gerson Lehrman Group (GLG) Consulting, Pfizer, Servier and Amcure; he is part of a Speakers' Bureau to Novartis; he has received research funding from AstraZeneca, Novartis, BeiGene and START; and he has received travel expenses from Roche/Genentech. The remaining authors report no competing interests. The original Article has not been corrected online.